within Pharmacolibrary.Drugs.N_NervousSystem.N01B_AnestheticsLocal.N01BB20_LidocaineCombinations;

model LidocaineCombinations
  extends Pharmacolibrary.Drugs.ATC.N.N01BB20;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N01BB20</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lidocaine, in combination with other agents, is used as a local anesthetic and antiarrhythmic. Such combinations may include vasoconstrictors like epinephrine or other local anesthetics. ATC code N01BB20 covers such unspecified combinations, which are generally used for local or regional anesthesia. Lidocaine combinations remain in clinical use today, especially for enhanced efficacy or duration of anesthesia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals after intravenous administration of lidocaine with epinephrine, based on primary literature describing lidocaine PK, as PK for ATC N01BB20 combinations specifically are not separately reported.</p><h4>References</h4><ol><li><p>Beaussier, M, et al., &amp; Mercadal, L (2018). Perioperative Use of Intravenous Lidocaine. <i>Drugs</i> 78(12) 1229–1246. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0955-x&quot;>10.1007/s40265-018-0955-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30117019/&quot;>https://pubmed.ncbi.nlm.nih.gov/30117019</a></p></li><li><p>Hughes, LM, et al., &amp; Nestor, CC (2023). Alternatives to remifentanil for the analgesic component of total intravenous anaesthesia: a narrative review. <i>Anaesthesia</i> 78(5) 620–625. DOI:<a href=&quot;https://doi.org/10.1111/anae.15952&quot;>10.1111/anae.15952</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36562193/&quot;>https://pubmed.ncbi.nlm.nih.gov/36562193</a></p></li><li><p>van Haren, F, et al., &amp; Steegers, M (2020). Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 26(8) 1850–1856. DOI:<a href=&quot;https://doi.org/10.1177/1078155220905011&quot;>10.1177/1078155220905011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32075507/&quot;>https://pubmed.ncbi.nlm.nih.gov/32075507</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LidocaineCombinations;
